FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322502803> ?p ?o ?g. }

• W4322502803 endingPage "2131" @default.
• W4322502803 startingPage "2131" @default.
• W4322502803 abstract "Alzheimer’s disease (AD) is one of the progressive neurological disorders and the main cause of dementia all over the world. The multifactorial nature of Alzheimer’s disease is a reason for the lack of effective drugs as well as a basis for the development of new structural leads. In addition, the appalling side effects such as nausea, vomiting, loss of appetite, muscle cramps, and headaches associated with the marketed treatment modalities and many failed clinical trials significantly limit the use of drugs and alarm for a detailed understanding of disease heterogeneity and the development of preventive and multifaceted remedial approach desperately. With this motivation, we herein report a diverse series of piperidinyl-quinoline acylhydrazone therapeutics as selective as well as potent inhibitors of cholinesterase enzymes. Ultrasound-assisted conjugation of 6/8-methyl-2-(piperidin-1-yl)quinoline-3-carbaldehydes (4a,b) and (un)substituted aromatic acid hydrazides (7a-m) provided facile access to target compounds (8a-m and 9a-j) in 4–6 min in excellent yields. The structures were fully established using spectroscopic techniques such as FTIR, 1H- and 13C NMR, and purity was estimated using elemental analysis. The synthesized compounds were investigated for their cholinesterase inhibitory potential. In vitro enzymatic studies revealed potent and selective inhibitors of AChE and BuChE. Compound 8c showed remarkable results and emerged as a lead candidate for the inhibition of AChE with an IC50 value of 5.3 ± 0.51 µM. The inhibitory strength of the optimal compound was 3-fold higher compared to neostigmine (IC50 = 16.3 ± 1.12 µM). Compound 8g exhibited the highest potency and inhibited the BuChE selectively with an IC50 value of 1.31 ± 0.05 µM. Several compounds, such as 8a-c, also displayed dual inhibitory strength, and acquired data were superior to the standard drugs. In vitro results were further supported by molecular docking analysis, where potent compounds revealed various important interactions with the key amino acid residues in the active site of both enzymes. Molecular dynamics simulation data, as well as physicochemical properties of the lead compounds, supported the identified class of hybrid compounds as a promising avenue for the discovery and development of new molecules for multifactorial diseases, such as Alzheimer’s disease (AD)." @default.
• W4322502803 created "2023-02-28" @default.
• W4322502803 creator A5003144386 @default.
• W4322502803 creator A5005596542 @default.
• W4322502803 creator A5019780164 @default.
• W4322502803 creator A5022390750 @default.
• W4322502803 creator A5043549980 @default.
• W4322502803 creator A5050635944 @default.
• W4322502803 creator A5053913642 @default.
• W4322502803 creator A5057012047 @default.
• W4322502803 creator A5059891438 @default.
• W4322502803 creator A5079172472 @default.
• W4322502803 creator A5081288881 @default.
• W4322502803 creator A5083023309 @default.
• W4322502803 date "2023-02-24" @default.
• W4322502803 modified "2023-09-27" @default.
• W4322502803 title "Ultrasound-Assisted Synthesis of Piperidinyl-Quinoline Acylhydrazones as New Anti-Alzheimer’s Agents: Assessment of Cholinesterase Inhibitory Profile, Molecular Docking Analysis, and Drug-like Properties" @default.
• W4322502803 cites W1092401495 @default.
• W4322502803 cites W1762587064 @default.
• W4322502803 cites W1967242229 @default.
• W4322502803 cites W1971048984 @default.
• W4322502803 cites W1985959814 @default.
• W4322502803 cites W1986476355 @default.
• W4322502803 cites W1992805793 @default.
• W4322502803 cites W1999336467 @default.
• W4322502803 cites W2001664582 @default.
• W4322502803 cites W2001732293 @default.
• W4322502803 cites W2005481380 @default.
• W4322502803 cites W2006944869 @default.
• W4322502803 cites W2007666107 @default.
• W4322502803 cites W2008648606 @default.
• W4322502803 cites W2016282741 @default.
• W4322502803 cites W2017606063 @default.
• W4322502803 cites W2018435704 @default.
• W4322502803 cites W2025022665 @default.
• W4322502803 cites W2025190578 @default.
• W4322502803 cites W2028638859 @default.
• W4322502803 cites W2039069312 @default.
• W4322502803 cites W2045535066 @default.
• W4322502803 cites W2046159507 @default.
• W4322502803 cites W2047112969 @default.
• W4322502803 cites W2047420624 @default.
• W4322502803 cites W2052606088 @default.
• W4322502803 cites W2055855522 @default.
• W4322502803 cites W2065281634 @default.
• W4322502803 cites W2075304800 @default.
• W4322502803 cites W2081830462 @default.
• W4322502803 cites W2085663480 @default.
• W4322502803 cites W2090663532 @default.
• W4322502803 cites W2104182950 @default.
• W4322502803 cites W2112006614 @default.
• W4322502803 cites W2114421026 @default.
• W4322502803 cites W2116664498 @default.
• W4322502803 cites W2124135429 @default.
• W4322502803 cites W2152477371 @default.
• W4322502803 cites W2324549918 @default.
• W4322502803 cites W2396930286 @default.
• W4322502803 cites W2593436234 @default.
• W4322502803 cites W2739470506 @default.
• W4322502803 cites W2789752300 @default.
• W4322502803 cites W2792863067 @default.
• W4322502803 cites W2885843511 @default.
• W4322502803 cites W3041936346 @default.
• W4322502803 cites W3047727745 @default.
• W4322502803 cites W3123640346 @default.
• W4322502803 cites W3123893662 @default.
• W4322502803 cites W3156026222 @default.
• W4322502803 cites W3194396237 @default.
• W4322502803 cites W3210231795 @default.
• W4322502803 cites W3216337644 @default.
• W4322502803 cites W4214535054 @default.
• W4322502803 cites W4248650858 @default.
• W4322502803 cites W4295277120 @default.
• W4322502803 doi "https://doi.org/10.3390/molecules28052131" @default.
• W4322502803 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36903376" @default.
• W4322502803 hasPublicationYear "2023" @default.
• W4322502803 type Work @default.
• W4322502803 citedByCount "0" @default.
• W4322502803 crossrefType "journal-article" @default.
• W4322502803 hasAuthorship W4322502803A5003144386 @default.
• W4322502803 hasAuthorship W4322502803A5005596542 @default.
• W4322502803 hasAuthorship W4322502803A5019780164 @default.
• W4322502803 hasAuthorship W4322502803A5022390750 @default.
• W4322502803 hasAuthorship W4322502803A5043549980 @default.
• W4322502803 hasAuthorship W4322502803A5050635944 @default.
• W4322502803 hasAuthorship W4322502803A5053913642 @default.
• W4322502803 hasAuthorship W4322502803A5057012047 @default.
• W4322502803 hasAuthorship W4322502803A5059891438 @default.
• W4322502803 hasAuthorship W4322502803A5079172472 @default.
• W4322502803 hasAuthorship W4322502803A5081288881 @default.
• W4322502803 hasAuthorship W4322502803A5083023309 @default.
• W4322502803 hasBestOaLocation W43225028031 @default.
• W4322502803 hasConcept C159110408 @default.
• W4322502803 hasConcept C178790620 @default.
• W4322502803 hasConcept C181199279 @default.
• W4322502803 hasConcept C185592680 @default.
• W4322502803 hasConcept C21951064 @default.
• W4322502803 hasConcept C2776309666 @default.

• next